Zeynep Bas
Overview
Explore the profile of Zeynep Bas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dockery P, DeSimone J, Liu C, Achuck K, Hamburger J, Bas Z, et al.
Can J Ophthalmol
. 2023 Dec;
59(5):329-334.
PMID: 38040029
Objective: To evaluate the effectiveness of preventing metastasis for each major treatment modality for iris melanoma. Design: Retrospective case series. Participants: Three hundred consecutive eyes with iris melanoma at a...
2.
Bas Z, Grant-Kels J, Shields C
Clin Dermatol
. 2023 Oct;
42(1):56-61.
PMID: 37890680
Uveal melanoma (UM) is the most common primary eye malignancy. Despite excellent local tumor rates, UM is a life-threatening disease with moderate systemic metastatic rates. In the past, certain clinical...
3.
Bas Z, Sajjadi Z, Shields C
Retina
. 2023 Sep;
43(11):1842-1851.
PMID: 37657072
Purpose: To describe the clinical and imaging features of sarcoid granuloma of the choroid and ciliary body. Methods: Retrospective case series of patients with choroid and/or ciliary body sarcoid granuloma...
4.
Shields C, Samuelson A, Oh G, DeSimone J, Sajjadi Z, Bas Z, et al.
Invest Ophthalmol Vis Sci
. 2023 Jul;
64(10):7.
PMID: 37418273
Purpose: To evaluate cumulative incidence of metastasis at specific timepoints after treatment of uveal melanoma in a large cohort of patients and to provide comparison of conditional outcomes in the...
5.
Shelukar S, Fernandez C, Bas Z, Komarnicky L, Lally S, Shields C, et al.
Chin Clin Oncol
. 2023 Jan;
11(6):44.
PMID: 36632978
Background: The first line definitive treatment for early-stage indolent B-cell lymphoma is radiation therapy (RT). Due to the sensitivity of orbital structures to radiation, ultra-low-dose RT (4 Gy in 2...
6.
Bas Z, Dockery P, Lally S, Shields J, Shields C
Ophthalmic Plast Reconstr Surg
. 2023 Jan;
39(1):49-57.
PMID: 36598390
Purpose: To compare the clinical features at presentation and treatment outcomes of conjunctival melanoma by absence/presence of orbital invasion. Methods: A retrospective review of patients with conjunctival melanoma managed at...
7.
Bas Z, Sharpe J, Yaghy A, Zhang Q, Shields C, Hyman L
Ophthalmol Sci
. 2022 Nov;
3(1):100227.
PMID: 36439695
Purpose: To estimate the prevalence of eyelid cancers in the American Academy of Ophthalmology Intelligent Research in Sight (IRIS) Registry and evaluate the associated factors. Design: Retrospective IRIS Registry database...
8.
Shields C, Dockery P, Mayro E, Bas Z, Yaghy A, Lally S, et al.
Saudi J Ophthalmol
. 2022 Oct;
36(3):308-314.
PMID: 36276251
Purpose: To understand conditional prognostic value of the Cancer Genome Atlas (TCGA) for uveal melanoma metastasis based on event-free survival at 1, 2, 3, 4, and 5 years. Methods: A...
9.
Gelmi M, Bas Z, Malkani K, Ganguly A, Shields C, Jager M
Ophthalmology
. 2022 Apr;
129(7):e79-e80.
PMID: 35431092
No abstract available.
10.
Shields C, Bas Z, Laiton A, Silva A, Sheikh A, Lally S, et al.
Eye (Lond)
. 2022 Feb;
37(5):815-822.
PMID: 35217824
In this review we discuss several recent concepts regarding retinoblastoma control and its impact. In a cohort of 482 patients with solitary unilateral retinoblastoma revealed germline mutation in 16% and...